No Data
Individual stock information.
DWTI<4576.T> rebounded sharply. On the 18th, the company announced that it received notification from its licensing partner Kowa (Nagoya) that the administration to subjects in the Global Phase 3 clinical trial of the eye drop "K-321," which contains the active ingredient Rhok kinase inhibitor "Ripassizil hydrochloride hydrate," has been completed. Follow-up observations for the subjects are expected to be completed by the end of October. Trenders<6069.T> also rebounded. zenpl, a company engaged in planning, producing, and managing various events.
Trenders are rebounding, viewing the subsidiary acquisition of zenplus as a material factor.
Trenders <6069.T> rebounded, reaching a temporary high of 870 yen, up 8 yen. After the close on the 18th, it was announced that they decided to acquire Stocks of zenplus (located in Chuo-ku, Tokyo) and make it a subsidiary, which was seen as positive news. Zenplus is engaged in comprehensive event production, including planning, production, and Operation of various events, as well as space design, casting, and planning and production of promotional tools. With this subsidiary acquisition, the company aims to strengthen its strengths in SNS (Social Networking).
Stable, with the decline in US stocks as a burden [Emerging Markets Individual Stock Global Strategy]
[Emerging Markets Individual Stock Global Strategy] Today's Emerging Markets are expected to show strong performance. In the U.S. stock market yesterday, on the 18th, the Dow Inc. fell by 260.32 points (-0.62%) to 41,581.31, marking a decline for the first time in three days. Profit-taking sales, particularly in high-tech sectors, and adjustment selling ahead of the Federal Open Market Committee (FOMC) announcement weighed on stock prices, while reports stating that Russia agreed to limit attacks on Ukraine's infrastructure in the U.S.-Russia summit served as a supporting factor for stock prices.
CINC, Good Patch and others.
The share buyback by CINCF has a maximum of 0.52 million shares (15.42% of the total shares issued) and will be purchased on the 19th through ToSTNeT-3. DWTI has completed the administration of the treatment for corneal endothelial degeneration, "K-321", in the Global Phase III clinical trial. KAIOM has signed a business partnership agreement with SRD, which handles clinical development and regulatory support for Pharmaceuticals and Medical Devices.
Key points of interest for the PTS on the 18th = Tohradiator, Goodpatch, Az Planning, ETC.
▽ Toho Radiator <7235.T> has revised upward its consolidated financial estimates and dividend estimates for the fiscal year ending in March 2025, and also announced a share buyback. ▽ Goodpatch <7351.T> has revised upward its consolidated financial estimates for the fiscal year ending in August 2025. ▽ Azukikaku <3490.T> has revised upward its consolidated profit estimates for the fiscal year ending in February 2025. ▽ Sisroke <2480.T> has established a shareholder benefit program and will present Quo cards. ▽ Metapra <3350.T> has announced additional purchases of Bitcoin. ▽ Trenders <6069.T> has completed an event company called zen.
Trenders: Extraordinary Report